Form 8-K - Current report:
SEC Accession No. 0001564590-22-010202
Filing Date
2022-03-15
Accepted
2022-03-15 06:03:29
Documents
14
Period of Report
2022-03-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K idya-8k_20220315.htm   iXBRL 8-K 34388
2 EX-99.1 idya-ex991_6.htm EX-99.1 223156
3 GRAPHIC gvwj5ve3oodj000001.jpg GRAPHIC 3749
  Complete submission text file 0001564590-22-010202.txt   414102

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA idya-20220315.xsd EX-101.SCH 5697
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE idya-20220315_lab.xml EX-101.LAB 20178
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE idya-20220315_pre.xml EX-101.PRE 12037
8 EXTRACTED XBRL INSTANCE DOCUMENT idya-8k_20220315_htm.xml XML 3693
Mailing Address 7000 SHORELINE COURT, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 7000 SHORELINE COURT, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-443-6209
IDEAYA Biosciences, Inc. (Filer) CIK: 0001676725 (see all company filings)

EIN.: 474268251 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38915 | Film No.: 22738857
SIC: 2834 Pharmaceutical Preparations